RE: Voleon Short position up to 1.03%11 Aug 2020 18:26
RBMInvest 16:10
"It isn't a five minute job to buy out a company. Huge amount of due diligence for a company like AZN to go through and to ensure that NCYT were the 'real deal' and not another wannabe.
Whilst doing that DD, you might want to do what you could to suppress the target's SP though. Just saying....".
You might also want to suppress the target's SP whilst waiting to see if the Govnt is going to award part of the £5 Bn (over 2 yrs) Govnt cash pile for Covid-19 testing etc to AZN.
No contract, or materially insignificant award, MIGHT change the PoV of AZN board, as NCYT (assay supplier) would also not benefit.
Following provided for reference -
70.6 Mil shares in issue, so 30% = 21.18 Mil shares need to be acquired by prospective purchaser before they must make an offer.
II's (from Morningstar - up to date?):
Vatel Capital 4,784,384 6.77%
Legal and General 2,525909 3.58%
Board:
Graham D. Mullis 61,631 0.106
Mr. James Wakefield 36,839 0.063
Mr. J-P Crinelli 21,232 0.037
Directors deals in the last 12 months:
J Wakefield NED / Chman 36,839 0.05% 18.05.2020
Graham Mullis 61131 0.09% 18.05.2020
J-P Crinelli NED 21232 0.03% 26.05.2020
Andrew Heath NED 20000 0.03% 03.06.2020
Market cap:£215.41 million, (source H-L).
I suspect II's under 3% notification level, and some PI's own many more shares than the 3 board members above.